D. Boral Capital reaffirmed their buy rating on shares of Quince Therapeutics (NASDAQ:QNCX – Free Report) in a report published on Friday,Benzinga reports. Zacks Research upgraded Quince Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 26th. According to data from MarketBeat, Quince Therapeutics has a consensus rating of “Buy” and a consensus price target of $8.14. Get Quince Therapeutics alerts:Read Our Latest Report on QNCXQuince Therapeutics Stock PerformanceShares of NASDAQ QNCX opened at $1.61 on Friday. Further ReadingReceive News & Ratings for Quince Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quince Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.